19. ライソゾーム病 Lysosomal storage disease Clinical trials / Disease details
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-005544-18-ES (EUCTR) | 29/04/2015 | 16/02/2015 | Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients | A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients | Fabry disease MedDRA version: 18.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 | Protalix Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 1;Phase 2 | United States;Paraguay;Spain;United Kingdom | ||
| 2 | EUCTR2013-002554-78-ES (EUCTR) | 26/11/2013 | 20/09/2013 | An Extension of the PB102F01 study: A clinical study in patients with Fabry disease to assess the safety, tolerability, and the body processing of the medication PRX102, which will be given as an infusion. | An Extension of Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks (9 Months) to Adult Fabry Patients | Fabry disease MedDRA version: 14.1;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 | Protalix Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 1;Phase 2 | United States;Serbia;Paraguay;Spain;Australia;Israel;United Kingdom | ||
| 3 | EUCTR2012-004786-40-ES (EUCTR) | 13/11/2013 | 05/09/2013 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion to Adult Fabry Patients | A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients | Fabry disease MedDRA version: 16.1;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 Product Name: PRX102 Product Code: PRX102 INN or Proposed INN: PRX102 | Protalix Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 1/2 | United States;Serbia;Paraguay;Argentina;Spain;Australia;Israel;United Kingdom | ||
| 4 | EUCTR2013-002554-78-GB (EUCTR) | 29/08/2013 | 09/09/2013 | An Extension of the PB-102-F01 study: A clinical study in patients with Fabry disease to assess the safety, tolerability, and the body processing of the medication PRX102, which will be given as an infusion. | An Extension of Phase 1/2, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks (9 Months) to Adult Fabry Patients - PB-102-F02: Extension of the PB-102-F01 study (PRX-102 for ERT in Fabry Disease) | Fabry disease MedDRA version: 16.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: PRX-102 Product Code: PRX-102 INN or Proposed INN: PRX-102 | Protalix Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 1;Phase 2 | United States;Paraguay;Argentina;Spain;Australia;Israel;Chile;United Kingdom |